We are live on ! Find out more
IFRX icon

InflaRx

39 hedge funds and large institutions have $27.8M invested in InflaRx in 2023 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 11 increasing their positions, 14 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

722% more call options, than puts

Call options by funds: $74K | Put options by funds: $9K

3.32% less ownership

Funds ownership: 32.32%29% (-3.3%)

7% less funds holding

Funds holding: 4239 (-3)

21% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 14

38% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 8

51% less capital invested

Capital invested by funds: $56.8M → $27.8M (-$28.9M)

Holders
39
Holders Change
-3
Holders Change %
-7.14%
% of All Funds
0.57%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
5
Increased
11
Reduced
14
Closed
8
Calls
$74K
Puts
$9K
Net Calls
+$65K
Net Calls Change
-$131K

IFRX Hedge Fund Activity: Q4 2023 in Review

39 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in InflaRx (IFRX) for Q4 2023, worth a combined $27.8M — down 51% from $56.8M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of IFRX and 5 opened new positions — a net loss of 3 holders — while 14 trimmed existing stakes and 11 added.

The largest buyer was Citigroup, adding an estimated $2.06M. The largest seller was 683 Capital Management, cutting an estimated $2.54M.

  • 39 institutional investors held InflaRx (IFRX) as of Q4 2023, down from 42 in Q3 2023.
  • Funds reported $27.8M of InflaRx stock for Q4 2023, down 51% quarter-over-quarter.
  • 5 funds opened new InflaRx positions in Q4 2023 and 8 closed out, a net change of -3 holders.
  • The largest InflaRx buyer in Q4 2023 was Citigroup, an estimated $2.06M added.
  • The largest InflaRx seller in Q4 2023 was 683 Capital Management, an estimated $2.54M sold.

Based on aggregated 13F filings for Q4 2023.